Tumor-associated antigens presented by dendritic cells (TAA-DC)

Tumor-associated antigens (TAAs) presented by patient dendritic cells (DCs) represent a specialized class of therapeutic targets used in personalized cancer immunotherapy. Dendritic cells are professional antigen-presenting cells that play a critical role in bridging innate and adaptive immunity by capturing, processing, and presenting antigens to T cells (Banchereau & Steinman, 1998, Nature). In this therapeutic context, DCs are typically isolated from a patient, loaded ex vivo with TAAs—which can be specific proteins like Prostatic Acid Phosphatase (PAP) or a broad spectrum of antigens from whole tumor lysates—and then re-administered to the patient (Kantoff et al., 2010, NEJM). The primary biological function of this target complex is to induce the maturation and activation of cytotoxic T lymphocytes (CTLs) that can specifically recognize and eliminate tumor cells expressing those antigens. This approach is designed to overcome the immunosuppressive environment of the tumor and the poor immunogenicity of many cancer cells. While Sipuleucel-T was the first FDA-approved therapy utilizing this mechanism for prostate cancer, the field continues to evolve with vaccines targeting neoantigens and utilizing various loading techniques like mRNA electroporation (Anguille et al., 2014, Lancet Oncology).

Other names

Dendritic cell-presented tumor antigensAutologous dendritic cells pulsed with tumor antigensDC-presented TAAsDendritic cell-based cancer vaccineAntigen-loaded dendritic cells

Dendritic cells process and present tumor-associated antigens via MHC class I and II molecules to prime and activate tumor-specific cytotoxic T lymphocytes and helper T cells.